Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - June 13, 2018 Category: Endocrinology Authors: Bo Ahr én MD , Stephen L. Atkin MD , Guillaume Charpentier MD , Mark L. Warren MD , John P. H. Wilding MD , Sune Birch MSc , Anders Gaarsdal Holst MD , Lawrence A. Leiter MD Source Type: research